Patents Assigned to Introgen Therapeutics
-
Patent number: 6726907Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: GrantFiled: April 24, 2000Date of Patent: April 27, 2004Assignee: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah R. Wilson, Lucetta Caston
-
Patent number: 6689600Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.Type: GrantFiled: November 16, 1999Date of Patent: February 10, 2004Assignee: Introgen Therapeutics, Inc.Inventors: Zheng Wu, Shuyuan Zhang
-
Publication number: 20040009939Abstract: The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.Type: ApplicationFiled: March 3, 2003Publication date: January 15, 2004Applicants: Board of Regent, The University of Texas System, Introgen Therapeutics, Inc.Inventors: Sunil Chada, Abujiang Pataer, Abner Mhashilkar, Rajagopal Ramesh, Jack Roth, Steve Swisher
-
Publication number: 20030224354Abstract: The invention relates to methods for quantifying viral particles in preparations by detecting the intrinsic fluorescence of viral proteins and correlating this emission to a standard for that virus.Type: ApplicationFiled: May 29, 2003Publication date: December 4, 2003Applicant: INTROGEN THERAPEUTICS INC.Inventors: Shawn Gallagher, Richard Sublett
-
Publication number: 20030045499Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increased or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells.Type: ApplicationFiled: August 9, 2002Publication date: March 6, 2003Applicant: Vanderbilt University and Introgen Therapeutics, Inc.Inventors: Dmitry Gabrilovich, David Carbone, Sunil Chada, Abner Mhashilkar
-
Publication number: 20030008375Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: December 27, 2001Publication date: January 9, 2003Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho
-
Publication number: 20020182723Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: June 12, 2001Publication date: December 5, 2002Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Shawn Gallagher
-
Publication number: 20020177215Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: December 27, 2001Publication date: November 28, 2002Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho
-
Publication number: 20020031527Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.Type: ApplicationFiled: August 28, 2001Publication date: March 14, 2002Applicant: Introgen Therapeutics, Inc.Inventors: Zheng Wu, Shuyuan Zhang
-
Patent number: 6194191Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: GrantFiled: November 20, 1997Date of Patent: February 27, 2001Assignee: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho